Williamsville, NY, Dec. 13, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today changes to the Company’s management. “Over the past few months we have made rapid and significant progress in strengthening 22nd Century Group as we execute against our two growth strategies,” commented James W. Cornell, Director & Chairman of the Board of 22nd Century Group.
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
Q1 2020 22nd Century Group Inc Earnings Call
Williamsville, NY, April 28, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, will release first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens. The press release will be available on 22nd Century Group’s website at www.xxiicentury.com. In conjunction with the earnings release, the Company will host a conference call on Thursday, May 7, 2020, at 8:00 a.m. ET.
22nd Century Group, Inc. (NYSE American: XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, announced today that the Company and North Carolina State University ("NCSU"), have completed successful research field trials that have validated new non-GMO (genetically modified organism) methodologies for reducing nicotine in tobacco plants. The research was partially funded by 22nd Century and was conducted by NCSU’s Department of Crop and Soil Science with project oversight provided by 22nd Century’s R&D team. The research findings and paper can be viewed at the following link: https://doi.org/10.3389/fpls.2020.00368
Williamsville, NY, March 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE AMERICAN: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant research, announced that two studies published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR), report the use of cigarettes containing very low levels of nicotine did not lead to compensatory smoking, further refuting common misperceptions about these products. The two studies were led by Tracy T. Smith, PhD, Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina and Hollings Cancer Center and were co-authored by other leading researchers of very low nicotine content cigarettes, including Professor Dorothy Hatsukami, PhD and Professor Eric Donny, PhD.
WILLIAMSVILLE, NY, April 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine content tobacco and hemp/cannabis plant genetics research and development, announced today that the U.S. Food and Drug Administration (FDA) has set May 18, 2020 as the deadline for the submission of public comments on the Company’s Modified Risk Tobacco Product (MRTP) Application. 22nd Century’s MRTP application seeks authorization from the FDA to allow the Company to market its reduced nicotine content cigarettes under the brand name VLN®, with pack and advertising claims stating that the product contains 95% less nicotine than conventional tobacco cigarettes, as well as related claims regarding reduced nicotine exposure.
22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant genetics research and development, yesterday filed its Annual Report on Form 10-K for the year ended December 31, 2019. A supplemental letter from Michael Zercher, President and Chief Operating Officer to shareholders is available in the Investor section of the Company’s website.
Williamsville, NY, Dec. 17, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes are “appropriate for the protection of the public health,” and the FDA has issued marketing orders to permit the sale of these products in the U.S. This FDA authorization follows the FDA’s review of the Premarket Tobacco Product Applications (PMTA) previously submitted by 22nd Century Group. “FDA authorization of 22nd Century’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes is a major milestone in our efforts to drive meaningful change in the tobacco industry,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.
Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes. “We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.
Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.
Williamsville, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today the initial closing of an investment in Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million, in a combination of cash and 22nd Century stock in exchange for Panacea-issued debt and preferred equity.
Anyone researching 22nd Century Group, Inc. (NYSEMKT:XXII) might want to consider the historical volatility of the...
WILLIAMSVILLE, N.Y., March 10, 2020 -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and.
WILLIAMSVILLE, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant genetics research, announced today that lead scientists from 22nd Century Group and KeyGene have assembled a high quality genome sequence of two hemp/cannabis lines and established a new, proprietary hemp/cannabis bioinformatics platform. Both are believed to be among the highest quality, hemp/cannabis reference genomes in the world. “These exciting, new developments are already enabling the rapid breeding of new and proprietary hemp/cannabis plant lines with truly remarkable and potentially novel medicinal cannabinoid profiles,” said Michael Zercher, President & Chief Operating Officer of 22nd Century Group.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Williamsville, NY, March 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE AMERICAN: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant research, announced that two studies published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR), report the use of cigarettes containing very low levels of nicotine did not lead to compensatory smoking, further refuting common misperceptions about these products. The two studies were led by Tracy T. Smith, PhD, Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina and Hollings Cancer Center and were co-authored by other leading researchers of very low nicotine content cigarettes, including Professor Dorothy Hatsukami, PhD and Professor Eric Donny, PhD.
22nd Century Group, Inc. (NYSE American: XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, today reported results for the first quarter ended March 31, 2020.
Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, announced today that the Company will hold its 2020 Annual Meeting of Stockholders using a virtual meeting format. The decision to move to a virtual meeting was done in order to protect the health and safety of meeting participants during the coronavirus (COVID-19) pandemic. The live webcast will be available under the Events tab on the Investor Relations section of the Company’s website at www.xxiicentury.com and will be archived for at least 90 days.
Investments are anticipated to total $24 million, in a combination of cash and 22nd Century stock. “Our objective is to build a leading, profitable business in the fast-growing, emerging, legal hemp/cannabis space, and Panacea is a rapidly-growing, vertically-integrated, consumer-facing business with a very strong management team," Cliff Fleet, President and CEO of 22nd Century Group said in a statement.